Xarelto Lawsuit Plaintiffs Find Support Through Study Published In BMJ Highlighting Potential Twofold Increase In GI Bleed Risk

February 29, 2016 – – BloodThinnerHelp.com reports on several study results which may now connect the use of anticoagulant drug Xarelto to an elevated risk of serious and sudden bleeding episodes among patients, including spontaneous vitreous hemorrhages, (or eye bleeds), stomach bleeds, brain bleeds, internal gastrointestinal bleeds, and more. The concerning results, however, may help plaintiffs currently in mounting lawsuits again Xarelto’s manufacturers to gain some additional research-based support.

The increasing number of Xarelto lawsuits were transferred to Eastern Louisiana after being filed in federal courts across the country. The transfer occurred when they were consolidated by the U.S. Judicial Panel on multidistrict litigation and formed into MDL No. 2592. This consolidation was possible due to the fact that all plaintiffs share similar allegations against the same two defendants: Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson). MDL cases now number over 2,800, and are joined by another mass tort group of more than 550 lawsuits in Philadelphia, Pennsylvania.

A study published in JAMA Ophthalmology on June 25, 2015, appears to highlight a connection between patient use of rivaroxaban (Xarelto’s generic form) and an increased risk of the sudden development of hemorrhages within the eyes. Physicians who researched this noted that they had discovered that “The risk of hemorrhage may be particularly elevated during the transition period when patients are switched from baseline anticoagulant to rivaroxaban therapy and are taking both anticoagulants simultaneously.” This is important and concerning information for patients who have taken traditional blood thinners before taking Xarelto. As a new-generation anticoagulant, this is likely the case for many.

Since approving Xarelto in 2011, The U.S. Food and Drug Administration has given it two black box warnings. Black box warnings are the most strict warning a product can be given before being completely removed from the market.

Later, another study connected potential health problems to the use of Xarelto, and was published in an April, 2015 issue of BMJ. The details noted that results of this study showed that Xarelto (rivaroxaban) use may actually double a patient’s risk of suffering from gastrointestinal bleeding when compared to patients using traditional anticoagulant warfarin. After completing this study, researchers stated, “…we cannot rule out…a more than twofold higher risk of bleeding with rivaroxaban compared with warfarin.”

Attorney Joseph Osborne is currently working to assist anyone who may have suffered from health complications which they believe were caused by Xarelto use. These individuals are entitled to explore their legal rights fully. In addition, they may qualify for significant compensation. To encourage any potential victims to pursue their rightful justice, Attorney Osborne is offering complimentary legal consultations for qualifying individuals at this time.

To request more information on Xarelto bleeding lawsuits, or to ask questions, please contact attorney Joseph Osborne by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60008412